[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100532079":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":18,"centralContacts":25,"locations":31,"responsibleParty":48,"collaborators":18,"id":50,"slug":51,"hasResults":52,"nctId":53,"briefTitle":54,"officialTitle":55,"acronym":18,"eligibilityCriteria":56,"healthyVolunteers":52,"sex":57,"minAge":58,"maxAge":18,"enrollmentInfo":59,"targetDuration":18,"studyType":62,"phases":63,"briefSummary":65,"conditions":66,"keywords":18,"overallStatus":34,"whyStopped":18,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},{"fullName":5,"class":6},"Institute of Hematology & Blood Diseases Hospital, China","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Intervention group","EXPERIMENTAL","Remind patients to test their immune status among 120-180 days post-transplantation. Physicians assessed the risk level of patients in the intervention group based on their immune status on days 91-180 using the CIRS.",[13],"Behavioral: Health monitoring and regular return follow-up reminders",{"label":15,"type":16,"description":17,"interventionNames":18},"Control group","NO_INTERVENTION","Only remind patients to test their immune status among 120-180 days post-transplantation.",null,[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":18},"BEHAVIORAL","Health monitoring and regular return follow-up reminders","Health monitoring \\& reminders for blood tests and follow-up visits until 1 year post-transplant",[9],[26],{"name":27,"role":28,"phone":29,"phoneExt":18,"email":30},"Yahui Feng, MS","CONTACT","022-23909051","fengyahui@ihcams.ac.cn",[32],{"facility":33,"status":34,"city":35,"state":36,"zip":37,"country":38,"countryCode":39,"cosmosGeoPoint":40,"geoPoint":45,"contacts":46},"Institute of Hematology & Blood Diseases Hospital","RECRUITING","Tianjin","Tianjin Municipality","300020","China","CN",{"type":41,"coordinates":42},"Point",[43,44],117.17667,39.14222,{"lat":44,"lon":43},[47],{"name":27,"role":28,"phone":29,"phoneExt":18,"email":30},{"type":49,"investigatorFullName":18,"investigatorTitle":18,"investigatorAffiliation":18,"oldNameTitle":18,"oldOrganization":18},"SPONSOR","100532079","using-the-composite-immune-risk-score-to-assess-and-modulate-the-patients-post-transplant-immune-reconstitution-100532079",false,"NCT06208137","Using the Composite Immune Risk Score to Assess and Modulate the Patient's Post-transplant Immune Reconstitution.","Using the Composite Immune Risk Score to Assess and Modulate the Patient's Immune Reconstitution After Allogeneic Hematopoietic Stem Cell Transplantation, a Prospective, Multicenter, Randomized Controlled Study.","Inclusion Criteria:\n\n* 1\\) Patients must be ≥ 16 years of age;\n* 2\\) Patients receiving haploidentical allo-HSCT;\n* 3\\) Patients have to sign an informed consent form before the start of the research procedure.\n\nExclusion Criteria:\n\n* 1\\) Tandem transplantation or multiple transplantations;\n* 2\\) Mental or other medical conditions that make the patients unable to comply with the research treatment and monitoring requirements;\n* 3\\) Patients who are ineligible for the study due to other factors, or will bear great risk if participating in the study.","ALL","16 Years",{"count":60,"type":61},456,"ESTIMATED","INTERVENTIONAL",[64],"NA","To assess the effectiveness of interventions including health monitoring and regular return follow-up reminders for patients with a high Composite Immune Risk Score.",[67],"Transplant-Related Disorder","2024-08-11",{"date":70,"type":71},"2024-08-13","ACTUAL",{"date":73,"type":71},"2024-02-29",{"date":75,"type":61},"2028-04-01",{"name":5,"class":6},1]